ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Accounts Receivables history
Currency unavailable · from the cash flow
No Accounts Receivables data reported for this period type.
Accounts Receivables vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $13.31M USD | +6.6% | — | 29.4% | |
| LTM Mar 2026 | $13.03M USD | -178.8% | — | 16.3% | |
| LTM Mar 2026 | $8.33M USD | — | — | 904.4% | |
| LTM Mar 2026 | $4.8M USD | +1478.7% | — | 15.0% | |
| LTM Mar 2026 | $177.78K USD | +291.8% | — | 0.2% | |
| LTM Mar 2026 | $17K USD | +200.0% | — | 0.4% | |
| LTM Mar 2026 | $8.07K USD | -96.4% | +481.9% | — | |
| LTM Mar 2026 | €0 EUR | — | — | 0.0% | |
| FY2025 | $0 USD | — | — | 0.0% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | +103.3% | +481.9% | 7.7% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.